Nektar Therapeutics (NKTR) Revenue (2010 - 2026)

Nektar Therapeutics' Revenue history runs 17 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• On a quarterly basis, Revenue rose 3.83% year-over-year to $10.9 million in Q1 2026; TTM through Mar 2026 was $55.6 million, a 36.24% decrease from a year earlier, with the FY2025 full-year figure at $55.2 million, down 43.89% from the prior year.
• Revenue retreated to $10.9 million in Q1 2026 per NKTR's latest filing, from $21.8 million in the prior quarter.
• Across five years, Revenue topped out at $29.2 million in Q4 2024 and bottomed at $10.5 million in Q1 2025.
• The 5-year median for Revenue is $21.8 million (2025), against an average of $20.4 million.
• Across the five-year window, Revenue rose 22.15% in 2024 and slumped 52.42% in 2025, its largest moves.
• Year by year, Revenue stood at $22.0 million in 2022, then increased by 8.45% to $23.9 million in 2023, then grew by 22.15% to $29.2 million in 2024, then dropped by 25.25% to $21.8 million in 2025, then plunged by 50.19% to $10.9 million in 2026.
• Per Business Quant, the three latest NKTR Revenue figures stand at $10.9 million (Q1 2026), $21.8 million (Q4 2025), and $11.8 million (Q3 2025).